Bristol Myers Squibb has entered a $15 billion partnership with China's Hengrui Pharma to develop new cancer drugs [1].
The agreement signals a strategic pivot for the U.S. pharmaceutical giant as it seeks to refresh its drug pipeline. By leveraging China's rapidly expanding biotech sector, the company aims to secure new therapeutic candidates to maintain its competitive edge in oncology [2, 3].
Chris Boerner, CEO of Bristol Myers Squibb, said the partnership during the American Society of Clinical Oncology annual meeting on May 15, 2026 [1, 4]. The collaboration is designed to integrate Hengrui's research capabilities with the global reach of BMS [1].
Financial terms of the deal include an up-front payment of $600 million to Hengrui [5]. Additionally, as part of the broader strategic restructuring in the region, BMS is selling a 60 percent stake in its China joint venture [6].
This move comes as China's biotech industry experiences a significant boom, attracting global pharmaceutical firms looking for innovation outside traditional Western hubs [2, 3]. The partnership focuses specifically on oncology, aligning with the goals of the ASCO meeting where the announcement was highlighted [1, 4].
Boerner said the partnership is a key part of the company's strategy to tap into the biotech growth occurring in China [1]. The deal allows BMS to diversify its research sources, and accelerate the development of next-generation cancer treatments [2, 3].
“BMS has entered a $15 billion partnership with China's Hengrui Pharma to develop new cancer drugs.”
This partnership reflects a broader trend of 'big pharma' firms seeking to mitigate pipeline exhaustion by outsourcing innovation to emerging biotech hubs. By investing heavily in Chinese research and restructuring its local joint venture, Bristol Myers Squibb is betting that the speed of innovation in China's biotech sector can offset the high costs and risks of internal drug discovery.
